A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma - PubMed (original) (raw)
Clinical Trial
A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma
J P Karpel et al. Chest. 1996 Sep.
Abstract
To evaluate the role of inhaled ipratropium bromide in acute asthma, a double-blind study of 384 emergency department patients compared the effect of the combination of ipratropium and albuterol with that of albuterol alone. Patients were randomized to receive nebulizer treatments with either 2.5 mg of albuterol or 2.5 mg of albuterol mixed with 0.5 mg of ipratropium bromide at entry and at 45 min. Spirometry, vital signs, and oxygen saturation were measured before and at 45 and 90 min following the nebulizer treatments. Serum potassium levels were obtained at entry and 90 min. The two groups did not differ significantly in age (mean +/- SD = 33.4 +/- 9.3 and 32.5 +/- 9.7 years for the albuterol and ipratropium group and the albuterol group, respectively), baseline FEV1 (mean +/- SD = 1.22 +/- 0.42 and 1.25 +/- 0.44 L respectively), or prior use of asthma medications. At 45 min, there were significantly more responders (15% increase in FEV1 over baseline) in the group receiving albuterol and ipratropium compared with albuterol and saline solution (85% and 78%, respectively; p = 0.045), but the median change in FEV1 from baseline did not differ (0.530 L for the albuterol and ipratropium group and 0.420 L for the albuterol and saline solution group; p = 0.347). By 90 min, the percentage of responders did not differ (88% and 89%, respectively), and the median change in FEV1 was 0.680 L for the group receiving albuterol and ipratropium and 0.650 L for the group receiving albuterol and saline solution (p = 0.693). There were no significant adverse events experienced by patients in either group. Furthermore, there were no significant differences in the number of patients requiring additional therapy in the emergency department or hospitalization. We conclude that in this population of inner city asthmatics, we were unable to demonstrate significant additive benefit of nebulized ipratropium bromide to nebulized albuterol.
Similar articles
- The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
Lanes SF, Garrett JE, Wentworth CE 3rd, Fitzgerald JM, Karpel JP. Lanes SF, et al. Chest. 1998 Aug;114(2):365-72. doi: 10.1378/chest.114.2.365. Chest. 1998. PMID: 9726716 Clinical Trial. - Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC, Little KS, Laughlin KR, Galbraith JM, Gustman PM, Murphy D, Kram JA, Hardie G, Reuter C, Ostransky D, McFarland K, Petty TL, Silvers W, Rennard SI, Mueller M, Repsher LH, Zuwallack RL, Vale R. Levin DC, et al. Am J Med. 1996 Jan 29;100(1A):40S-48S. doi: 10.1016/s0002-9343(96)80073-8. Am J Med. 1996. PMID: 8610716 Clinical Trial. - Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
Goggin N, Macarthur C, Parkin PC. Goggin N, et al. Arch Pediatr Adolesc Med. 2001 Dec;155(12):1329-34. doi: 10.1001/archpedi.155.12.1329. Arch Pediatr Adolesc Med. 2001. PMID: 11732951 Clinical Trial. - Combined anticholinergic therapy in the management of acute asthma.
Garrett JE. Garrett JE. Respirology. 1997;2 Suppl 1:S17-8. Respirology. 1997. PMID: 9400690 Review. - Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B, Markham A. Jarvis B, et al. Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006. Drugs Aging. 2001. PMID: 11419918 Review.
Cited by
- Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.
Rodrigo GJ, Castro-Rodriguez JA. Rodrigo GJ, et al. Thorax. 2005 Sep;60(9):740-6. doi: 10.1136/thx.2005.040444. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055613 Free PMC article. Review. - Paradoxical Bronchoconstriction with Short-Acting Beta Agonist.
Magee JS, Pittman LM, Jette-Kelly LA. Magee JS, et al. Am J Case Rep. 2018 Oct 9;19:1204-1207. doi: 10.12659/AJCR.910888. Am J Case Rep. 2018. PMID: 30297688 Free PMC article. - Discharge of the asthmatic patient.
Markoff BA, MacMillan JF Jr, Kumra V. Markoff BA, et al. Clin Rev Allergy Immunol. 2001 Jun;20(3):341-55. doi: 10.1385/CRIAI:20:3:341. Clin Rev Allergy Immunol. 2001. PMID: 11413903 Review. - Medical and ventilatory management of status asthmaticus.
Levy BD, Kitch B, Fanta CH. Levy BD, et al. Intensive Care Med. 1998 Feb;24(2):105-17. doi: 10.1007/s001340050530. Intensive Care Med. 1998. PMID: 9539066 Review. - Pharmacologic treatment of the adult hospitalized asthma patient.
Kreutzer ML, Louie S. Kreutzer ML, et al. Clin Rev Allergy Immunol. 2001 Jun;20(3):357-83. doi: 10.1385/CRIAI:20:3:357. Clin Rev Allergy Immunol. 2001. PMID: 11413904 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical